Erste Asset Management GmbH Increases Stake in Johnson & Johnson $JNJ

Key Points

• Erste Asset Management GmbH increased its stake in Johnson & Johnson by 28.8%, acquiring an additional 52,086 shares, bringing its total holdings to 233,107 shares worth approximately $38.7 million.
• The latest earnings report showed Johnson & Johnson achieved an EPS of $2.77, surpassing estimates, and a revenue of $23.74 billion, reflecting a 5.8% increase year-over-year.
• Johnson & Johnson announced a quarterly dividend of $1.30 per share, with an ex-dividend date of August 26th, representing a 2.9% yield.

Erste Asset Management GmbH raised its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 28.8% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 233,107 shares of the company's stock after buying an additional 52,086 shares during the period. Erste Asset Management GmbH's holdings in Johnson & Johnson were worth $38,658,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of JNJ. Elios Financial Group Inc. raised its stake in Johnson & Johnson by 1.5% during the 1st quarter. Elios Financial Group Inc. now owns 4,496 shares of the company's stock valued at $746,000 after acquiring an additional 66 shares in the last quarter. Atlantic Family Wealth LLC lifted its holdings in Johnson & Johnson by 4.4% in the first quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company's stock worth $266,000 after purchasing an additional 67 shares during the period. MBA Advisors LLC grew its position in Johnson & Johnson by 1.2% in the 1st quarter. MBA Advisors LLC now owns 5,553 shares of the company's stock valued at $921,000 after buying an additional 68 shares in the last quarter. Sovereign Financial Group Inc. increased its stake in Johnson & Johnson by 1.8% during the 1st quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company's stock valued at $651,000 after buying an additional 69 shares during the period. Finally, Nabity Jensen Investment Management Inc raised its position in shares of Johnson & Johnson by 1.5% during the 1st quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company's stock worth $767,000 after buying an additional 69 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on JNJ. Wall Street Zen lowered shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research note on Friday, July 18th. Piper Sandler reiterated an "overweight" rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Leerink Partnrs cut shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Bank of America boosted their target price on shares of Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a report on Thursday, July 17th. Finally, UBS Group raised their target price on shares of Johnson & Johnson from $180.00 to $190.00 and gave the stock a "buy" rating in a report on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have given a Hold rating to the company's stock. According to data from MarketBeat, Johnson & Johnson has a consensus rating of "Moderate Buy" and a consensus price target of $174.50.

Johnson & Johnson Price Performance

Shares of JNJ stock opened at $177.7060 on Wednesday. The firm has a market cap of $427.98 billion, a price-to-earnings ratio of 19.01, a PEG ratio of 2.24 and a beta of 0.41. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $178.18. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The stock has a 50-day moving average price of $162.13 and a 200 day moving average price of $158.73.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. The company had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company's revenue was up 5.8% compared to the same quarter last year. During the same period in the prior year, the company posted $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Research analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.9%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio (DPR) is 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.